Device Trial Radar · NCT07517237
taVNS + CCT for Neurocognitive Rehab
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Mar 12, 2026
Primary completion
Oct 26, 2026
Study completion Oct 26, 2026
Sponsor
- Lead sponsor
- Medical University of South CarolinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institutes of Health (NIH)
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with computerized cognitive training might help improve thinking abilities and mood. Participants will self-administer these treatment in their homes and undergo pre- and post-treatment assessments of thinking abilities and mood and brain MRIs.
Conditions
- Psychosocial Well-being
- Neurocognitive Function
- Cognitive Complaint
- Cognitive Dysfunction
Interventions
taVNSDevice
A Soterix Medical Handheld home-based taVNS device combined with web-based adaptive computerized cognitive training (CCT) will be self-administered for 10, 1 hour treatment sessions at home. CCT will be accessed via the web from a tablet or computer. The premise of a combined approach is that taVNS "primes" brain networks that are then engaged by CCT, synergistically enhancing cognitive benefits.
Computerized Cognitive TrainingDevice
CCT will be delivered through the online BrainHQ platform. Participants will engage in adaptive visual speed of processing training for approx. 30 minutes per session (10 sessions, total CCT time = 300 min).
Primary outcomes
What the sponsor says the trial is designed to measure.
- RetentionTime frame: From enrollment to the V2 post-treatment assessment (approximately 6 weeks).
- AdherenceTime frame: 10 treatments (T1-T10) over max span of 14 days.
- AcceptabilityTime frame: V1 (1 week pre-treatment), V2 (1 week post-treatment)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.